

Summer 8-6-2019

Impact of Diet on the Pathogenesis of Alzheimer's Disease

Katherine Faith Neder Bechdol
Georgia State University

Follow this and additional works at: https://scholarworks.gsu.edu/nutrition_mastersprojects

Recommended Citation

Bechdol, Katherine Faith Neder, "Impact of Diet on the Pathogenesis of Alzheimer's Disease." , Georgia State University, 2019.
https://scholarworks.gsu.edu/nutrition_mastersprojects/14

This Project is brought to you for free and open access by the Department of Nutrition at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Nutrition Masters Projects by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.

Katherine Bechdol

Impact of Diet on the Pathogenesis of Alzheimer's Disease

Summer 2019

Georgia State University

Introduction

Alzheimer's Disease (AD), the most common form of dementia, is a neurodegenerative disease characterized by a progressive loss of neural cells leading to nervous system dysfunction. The hallmark signs are memory loss and decreased abilities to make judgements and perform activities of daily living¹. Because of the increasing lifespan of humans, the projected number of people 65 years and older diagnosed with AD is expected to reach 13.8 million by the year 2050². Biologically, AD is characterized by deposition of beta-amyloid protein (A β) and tau neurofibrillary tangles (NFTs). The deposition of A β occurs due to the cleavage of amyloid precursor protein (APP) changing from α -secretase to β -secretase and γ -secretase. This change in enzymatic activity causes larger A β molecules to form which then stack on top of one another creating amyloid plaques³. NFTs accumulate when isoforms of tau, a microtubule-associated protein, begins to hyperphosphorylate and fold atypically¹. Over time, these accumulations of amyloid plaques and NFTs lead to brain shrinkage and atrophy causing the well documented signs of AD such as memory problems, impaired judgement, and personality changes^{1,4}.

AD is classified into two types, Familial Alzheimer's Disease (FAD) and Sporadic Alzheimer's Disease (SAD). FAD, also known as early-onset AD, accounts for approximately 5% of all cases and occurs via genetic inheritance, beginning between the ages of 40 and 60⁵. There are three genetic mutations that account for FAD, these are mutations in the genes that encode for presenilin 1 (a subunit of γ -secretase), presenilin 2 (assist in processing APP), and APP itself⁴. SAD, or late-onset AD, typically occurs after the age of 65. It is not entirely understood what causes SAD, but research indicates genetics, lifestyle, and environmental factors, such as diet, disease state, age, socioeconomic status, and educational level, impact its development⁵.

Hypotheses for AD development

Over the past several decades there have been many advances in AD research; however, the cause is still unknown. Development of AD follows a well-documented path, known as Braak staging. First described in 1991, Braak staging has six distinctive phases of AD grouped into three units based on the location of NFTs. Stages I-II occurs in the transentorhinal and entorhinal regions, III-IV are in the limbic allocortex and its adjacent neocortex, and V-VI are in the neocortex⁶. Once AD begins there is no reversing the disease; in order to better understand the disease researchers have hypothesized over the causes of disease progression. The main hypotheses include the amyloid, tau, oxidative stress, cholinergic, N-methyl-D-aspartate (NMDA) receptor, and altered calcium homeostasis⁷⁻¹¹. More recently, impaired glucose metabolism in the brain, pathogenic virus, and prion disease hypotheses have emerged as possible causes of AD^{10,12,13} (Figure 1). Each of these pathways will be explored in more detail but a brief description is included here. The amyloid and tau hypotheses are the most common as the presence of amyloid plaques and NFTs are the definition of AD. The amyloid hypothesis centers around the creation of amyloid plaques formed from longer sheets of $A\beta_{40-42}$ while the tau hypothesis focuses on the accumulation of NFTs leading to neuron death⁷. In oxidative stress, neuronal hypoxia caused by an increase in reactive oxygen species (ROS) occurs⁷. With the cholinergic hypothesis, cholinergic function is lost leading to a decrease in the neurotransmitter acetylcholine (ACh) and subsequent increases in cholinesterase⁸. At the NMDA receptor, neuronal death occurs after excitotoxicity causes increased glutamate and decreased NMDA receptors. The altered calcium homeostasis hypothesis focuses on altered mitochondrial function due to changes in enzymatic activity. This decreased mitochondrial function causes defects in the electron transport chain, leading to production and deposition of $A\beta$ ⁷. More recently, high

carbohydrate diets causing impaired glucose metabolism in the brain due to a decrease in lipoprotein creation in the liver has been proposed as a possible mechanism of action¹⁰. In 2018, researchers proposed certain viruses, with emphasis on herpes simplex virus, have the ability to stimulate the accumulation of A β ¹². Lastly, prion disease, which occurs when the prion protein causes normal proteins in the brain to misfold, is considered a possibility for AD development¹⁴. This hypothesis centers around cellular prion protein (PrP^C) acting as a cellular surface receptor for A β ¹³.

AD and nutrition

Not only are researchers divided on the mechanism for AD development, but the research into diet and its impact on these hypotheses is limited. A focus on the daily consumption of complex carbohydrates; including vegetables, whole grains, fruit, nuts, seeds, and legumes has been emphasized, with a strong correlation between adherence to a Mediterranean diet and overall cognitive performance^{7,15}. One study reported that consumption of vegetables, fruits, nuts, and fish were associated with improved subjective cognitive function when compared to the intake of meat and dairy¹⁵. A hybrid of the Mediterranean and Dietary Approach to Stop Hypertension (DASH) diets, the Mediterranean-DASH intervention for Neurodegenerative Delay (MIND) diet, has been developed to help delay the onset of cognitive decline^{16,17}. This diet is high in nutrients that research has shown to slow cognitive decline and includes "...folate, vitamin E, carotenoids, and flavonoids"¹⁶. Therefore, an emphasis is placed on adding berries and dark leafy greens, while not emphasizing large consumption of fruit, dairy, potato, and fish. To date, studies have shown that a high adherence to the MIND diet may play a protective role against AD development¹⁷.

Literature Review

1. Amyloid Hypothesis

The large majority of research surrounding diet and AD centers around the amyloid hypothesis and the deposition of amyloid plaques. In healthy brains, α -secretase cleaves the vast majority of APP, releasing shorter, harmless fragments of A β , such as A β ₂₅ and A β ₃₈. In the brains of AD patients, β -secretase followed by γ -secretase, are highly active and cleave APP in different locations, releasing longer A β proteins, like A β ₄₀ and A β ₄₂^{18,19}. Of these two longer proteins, more A β ₄₀ is produced; however, A β ₄₂ is more toxic due to a higher affinity for aggregating caused by its hydrophobic properties¹. Amyloid plaques are a buildup of these longer A β sheets. Experiments have shown nutrients found in common foods can mitigate A β -induced damage by increasing α -secretase, decreasing β -secretase and/or γ -secretase, disrupting amyloid plaques, autophagy, and/or clearing A β across the blood brain barrier (BBB) (Figure 2)²⁰⁻⁵¹.

Specific nutrients reviewed to determine their effect on amyloid plaques were docosahexaenoic acid (DHA), extra virgin olive oil (EVOO), resveratrol, curcumin, epigallocatechin gallate (EGCG), salvianolic acid B (Sal B), and the fat-soluble vitamins, A, D, E, and K. DHA is an omega-3 fatty acid that is anti-inflammatory and commonly found in flaxseed oil, chia seeds, walnuts, and fish (among other things)⁵². EVOO, a cooking oil used commonly in both the Mediterranean and MIND diets, is an unsaturated fat that contains various isoforms of vitamin E as well as various phenolic compounds, flavonoids, and lignans⁵³. Resveratrol, a polyphenol found in nuts, berries, wine, and dark chocolate, has strong antioxidant, anti-inflammatory, anti-cancer, and anti-ageing properties²⁰. Curcumin, a nutrient found in turmeric, curry powder, and ginger, displays similar antioxidant, anti-inflammatory, and anti-cancer properties as resveratrol²¹. EGCG, a major polyphenol and catechin found in green

tea has been shown to have neuroprotective effects²². Sal B is a water-soluble derivative of caffeic acid that has been commonly used in Chinese medicine to treat coronary artery disease and cerebrovascular diseases⁵⁴. Lastly, multiple research studies have shown a positive correlation between serum and plasma levels of fat-soluble vitamins and cognitive performance⁵⁵⁻⁶⁸. Interestingly, an association has also been found between individuals using a vitamin K antagonist for their anticoagulant medication, such as Warfarin, and cognitive impairment⁶⁹.

Activation of α -secretase

Compounds that have an ability to activate α -secretase would potentially be able to increase the production of harmless $A\beta$ leading to a decrease in the harmful $A\beta^{23}$. An in-vitro study showed Neuroprotection D1 (NPD1), an enzymatic derivative of DHA, was shown to activate α -secretase in a dose-dependent manner. In this study, overexpression of APP was induced in aging human neuronal-glia cells through transient-transfection with Swedish mutation APP. These cells were treated with NPD1 at concentrations of 0 nM, 50 nM, 100 nM, and 500 nM, with the greatest effect seen at 500 nM²³. A second in-vitro study analyzed resveratrol's ability to upregulate sirtuin 1 (SIRT1), a silent information regulator that is suppressed by $A\beta(25-35)$. SIRT1 downregulates Rho-associated protein kinase 1 (ROCK1), an inhibitor of α -secretase²⁰. This study incubated pheochromocytoma (PC12) cells with resveratrol at concentrations of 12.5 μ M, 25 μ M, 50 μ M, or 100 μ M 2 hours prior to the addition of 20 μ M $A\beta_{25-35}$ ²⁰. A significant increase of SIRT1 expression and a decrease in ROCK1 expression were seen in western blot analysis showing the potential of resveratrol to upregulate α -secretase²⁰. An in-vitro analysis looking into curcumins impact on human embryonic kidney cells (HEK293) overexpressing APP. Curcumin, tetrahydrocurcumin (THC), curcumin-isoleucine (Cur-Ile),

curcumin-phenylalanine (Cur-Phe), or curcumin-valine (Cur-Val) was added at a concentration of 50 μ M, with analysis showing Cur-Ile, Cur-Phe, and Cur-Val stimulated α -secretase expression²⁴. A second in-vitro study on curcumin conducted on PC12 cells showed that lower concentrations of curcumin were protective against A β -induced toxicity while higher concentrations increased toxicity²⁵.

Decreased activity of β -secretase and/or γ -secretase

Through decreasing enzymatic activity of β -secretase and/or γ -secretase, the continued production of harmful A β may decrease²³. An in-vitro study, looking at EGCG showed a 5-minute incubation of green tea infusion inhibited β -secretase activity by as much as 27%, which increased to 38% after 60 minutes²⁶. An in-vivo study utilizing an APP/Presenilin-1 (PS1) double-transgenic mouse study indicated EGCG was able to ameliorate learning and memory impairment as seen in a Passive Avoidance Test and Morris Water Maze. Mice treated with EGCG showed decreased concentrations of amyloid plaques, decreased concentrations of APP, and decreased apoptosis of neurons with researchers proposing this activity being in part due to EGCGs effects on γ -secretase⁷⁰.

When looking at in-vivo research, vitamin A deficiency has been shown to increase deposition of A β in the brain and cerebral blood with supplementation of all-trans retinoic acid improving cognitive function²⁷. One possible mechanism for this is through inhibiting β -secretase-dependent APP cleavage²⁸. In-vivo research into vitamin D has proposed a possible mechanism for clearing A β is vitamin D's ability to elevate neprilysin, an enzyme that is shown to degrade A β and reduce concentrations of β -secretase²⁹. Studies into vitamin D have shown significantly reduced amyloid plaques and improved cognitive performance with

supplementation of a D₃ enriched diet, although it is important to note that rats with normal vitamin D levels did not show improvement in spatial performance with D₃ supplementation²⁹⁻³².

Mechanisms by which vitamin E impacts AD include its effect on decreasing cholesterol synthesis. Studies have shown a strong positive correlation between hypercholesterolemia and A β production³³. The relationship between cholesterol and AD centers around cholesterol increasing the activity of β - and γ - secretase³⁴. Because vitamin E is a group of eight compounds, it can be confusing to know if it is a combination or just one of these isoforms that has the greatest benefit. Table 1 breaks down some of the research into the various forms of vitamin E as it relates to AD. Unfortunately, outcomes in human studies on vitamin E supplementation have ranged from reduced need of care and slowed disease progression to no effect or an increased cognitive decline³⁵⁻³⁸.

Disruption of amyloid plaques

Causing a conformation change in amyloid plaques has shown potential for decreasing overall amyloid load^{39-42,45}. An in-vitro analysis on resveratrol using PC12 cells showed 25 μ M resveratrol combined with 25 μ M purified A β 42 remodeled three A β 42 conformers—soluble oligomers, fibrillar intermediates, and amyloid fibrils—into an alternative aggregation that is unstructured and nontoxic³⁹. This occurs due to resveratrol binding to the N-terminus of A β 42 monomers, preventing the formation of oligomers longer than 1–2 nm. Similar results has been seen in-vitro utilizing curcumin⁴⁰. In an in-vitro analysis, Sal B showed a significant inhibition of the formation of A β 42 that was both dose and time-dependent. Although a mechanism for how Sal B inhibited A β 42 was not proposed, researchers indicated fibrils of A β were converted into deformed aggregates. Incubation with Sal B occurred up to 7 days with 100 μ M concentrations⁵⁴. Additional In-vitro studies into vitamin K have indicated it has the potential to be an effective

anti-amyloidogenic drug due to its inhibition of A β accumulation and toxicity through binding to the A β monomer⁴¹. Additionally, in-vitro analysis using human neuroblastoma cells (SH-S5Y5) showed DHA interrupted the microenvironment of tyrosine in the A β 42 backbone, thus reducing levels of soluble A β 42 oligomers and inhibiting the formation of A β 42 fibrils. While 5 μ M DHA had no significant effect on fibril formation, 10 μ M and 20 μ M DHA decreased fibril formation by 32% and 41%, respectively⁴².

EGCG has shown the ability to decrease A β generation in a dose-dependent manner, protect against A β -induced apoptosis, and inhibit fibrillization of A β ^{22,43,44}. A proposed mechanism for how EGCG is able to do this is via covalent bonding with A β , preventing its accumulation⁴⁵. It is important to note that EGCG is not the only catechin in green tea nor is it the only antioxidant. It is likely the inhibition activity seen in the green tea infusion is due to the cumulative effect of all of the bioactive compounds found in green tea. In one in-vivo study, α -secretase activity increased, overall plaque load was reduced by 50% and β -secretase and γ -secretase activity decreased. Researchers concluded oral administration of EGCG was more effective than injection^{24,43,46}.

Autophagy

Curcumin has also been shown to reduce A β 42 toxicity through an in-vivo study comparing the effects of curcumin supplementation in mice⁴⁷. After sacrifice, control mice showed well-formed amyloid plaques where treatment mice showed significantly reduced plaques in a dose dependent manner in both the hippocampus and cortex⁴⁷. This same in-vivo study showed an increase in autophagy of APP-rich organelles. Additionally, Morris water maze test after six months of treatment with either control, low concentration, or high concentration of curcumin revealed that mice completed the maze faster in a dose dependent manner. When the

brains of the mice were extracted and analyzed it was determined that curcumin acts through the PI3K/Akt/mTOR pathway to stimulate the autophagy of APP-rich organelles allowing for the survival and proliferation of cells⁴⁷. Although in-vitro and in-vivo research has shown the benefit of curcumin, two human studies, one a 6-month clinical trial and one a phase 2 double-blind study did not show any improvement in cognitive performance or levels of amyloid plaques^{48,49}. This can potentially be caused by curcumin's low bioavailability²¹.

In one study on ambulatory AD patients, peripheral blood mononuclear cells (PBMCs) were collected and differentiated into macrophages. These macrophages were incubated overnight with either 1,25-dihydroxyvitamin D₃ (1,25D₃) at a final concentration of 0.01 to 0.1 μM or curcuminoids at a concentration of 0.001 μM to 1 μM. Fluorescently labeled Aβ was also added, and fluorescence microscopy and enzyme-linked immunosorbent assay (ELISA) both revealed that 1,25D₃ increased clearance of Aβ through phagocytosis in all cells, and curcuminoids significantly assisted in only 50% of cells. 1,25D₃ stimulates transport of Aβ within the cell, while curcuminoids stimulate surface binding. It was determined *in silico* that 1,25D₃ binds to the genomic pocket of the vitamin D receptor (VDR), while curcuminoids binds to the non-genomic pocket⁵⁰.

Clearing Aβ across the Blood Brain Barrier

One in-vivo study looking at the effects of EVOO on Aβ burden, showed after three and six months of EVOO consumption, Aβ concentrations in mice brains were significantly reduced by 24% and 29% respectively. Researchers found this reduction in Aβ load was possibly associated with clearance across the blood brain barrier. Additionally, mice in the six-month treatment group showed improvement in the burrowing and nest construction test compared to control where mice in the three-month treatment group showed no improvement. Researchers

proposed that clearing A β across the BBB could potentially prevent an accumulation of amyloid plaques in the brain⁵¹.

2. Tau Hypothesis

The Tau hypothesis for AD development goes hand in hand with A β accumulation; the presence of both being the definitive diagnosis of AD⁷. Tau proteins assist in the formation of microtubules, promotion of microtubule stability, and synaptic plasticity. In the tau hypothesis, NFTs are produced in the brain. This occurs through a chain reaction starting with tau protein developing an unhealthy ratio of repeating amino acid sequences in the microtubule-binding domain. A normal tau protein has around 77 serine/threonine sites that allow for phosphorylation of the protein. When hyperphosphorylation occurs, tau's affinity for microtubules is decreased along with the overall stability of microtubules. As more tau proteins are hyperphosphorylated, they accumulate, forming NFTs. This accumulation of NFTs leads to neuron death and cognitive decline⁷¹.

In-vitro studies have demonstrated that grape seed phenol extract, tannic acid, and oleuropein (a compound found in olives) has the ability to inhibit the accumulation of tau by breaking up preformed tau peptide aggregates and inhibiting their accumulation⁷²⁻⁷⁴.

Additionally, in-vitro studies have shown grape seed phenol extract was able to breakdown preformed tau peptides⁷². In-vivo studies showed the effectiveness of grape seed phenol extract at reducing the phosphorylation of tau and EGCG at suppressing phosphorylated tau isoforms^{46,75,76}.

Similar to its effects on A β plaques, vitamins A and E have shown the potential to reduce the concentration of NFTs. Vitamin A shows this activity with supplementation of all-trans retinoic acid in in-vivo studies and is possibly due to retinoic acid's ability to prevent tau

phosphorylation^{27,77,78}. Vitamin E shows this action via trolox, an analog of vitamin E that is water soluble⁷⁹. A second in-vivo study showed supplementation with α -tocopherol caused suppressed development of NFTs⁸⁰.

3. Oxidative Stress

During oxidative stress, there is an imbalance between the production of ROS and their clearance from the body. As a result, neuronal hypoxia may occur, leading to neurodegeneration. Because the brain is more susceptible to free radical damage than other organs, oxidative damage can be both a potential cause of and result of A β deposition. The amyloid and oxidative stress hypotheses are closely linked due to APP and its derivatives causing excessive generation of ROS in mitochondria. This, coupled with oxidative stress, potentially causing increases in β -secretase and γ -secretase, leading to increased plaque deposition⁷.

ROS play a pivotal role in immune response and cell signaling and are created during normal physiological processes. In a healthy individual, endogenous antioxidant defense systems keep ROS at healthy levels⁷. Various mechanisms are known to increase the levels of ROS in the brains of patients with AD, including increasing amyloid plaque load and increasing excitotoxicity from the NMDA receptor⁸¹⁻⁸³. In order to maintain a healthy equilibrium between creation and degradation of ROS, a diet high in antioxidants is crucial⁷. Antioxidants scavenge ROS and inhibit their continued formation. By including antioxidants in the diet, they increase the effects of endogenous antioxidants⁸⁴.

Many vitamins, minerals, and polyphenols display antioxidant activity, including vitamins A, C, and E; selenium; and polyphenols such as resveratrol⁸⁵. Antioxidants are primarily found in plant-based foods, such as teas, nuts, berries, dark chocolate, and fruit⁸¹. Due to the importance of antioxidants, the creators of the MIND diet emphasized consumption of

complex carbohydrates. The MIND diet includes ten categories of brain healthy foods (“...green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, seafood, poultry, olive oil, and wine...”) and five categories of unhealthy foods (“...red meats, butter and stick margarine, cheese, pastries and sweets, and fried/fast foods...”) ¹⁶. In one study of preclinical AD patients, the MIND diet was significantly associated with a decreased risk of developing AD. Individuals in the highest quartile of compliance had a 53% reduction in AD compared to the lowest quartile ¹⁷.

Resveratrol can also act in combination with melatonin to attenuate oxidative stress associated with A β ₄₂. An in-vitro study using HT22 hippocampal cells determined A β ₁₋₄₂ induced cell death via oxidative stress in a dose dependent manner. Researchers measured levels of ROS as well as cell viability to show the effects of A β ₁₋₄₂ without treatment groups. The cell line was infected with 2 μ M A β ₁₋₄₂ and treated with 0.1 μ M to 20 μ M resveratrol and/or 1 μ M to 500 μ M melatonin. Using DCF fluorescence, it was determined that the maximum reduction of oxidative stress was achieved at concentrations of 20 μ M resveratrol and 500 μ M melatonin, and that co-treatment revealed synergistic effects. Spectrophotometry revealed that resveratrol and melatonin may reduce oxidative stress by preventing the depletion of glutathione, another antioxidant. A β treatment resulted in a glutathione decrease of 20%, and the addition of resveratrol and melatonin increased glutathione to at least control levels ⁸⁶. Another in-vitro study conducted rat primary cortex neurons using resveratrol as well as two other stilbenes, trans-4-hydroxystilbene (THS) and trans-3'4',3,5-tetrahydroxy-stilbene (PIC) showed the free radical scavenging ability of these compounds. THS showed the lowest effectiveness on ROS at 6.25%, followed by resveratrol at 13.07% and PIC at 26.82%. When compared with A β ₂₅₋₃₅, stilbenes

showed a significant dose-dependent decrease in ROS showing a possible neuroprotective effect of these nutraceuticals⁸⁷.

Cocoa extract is another high antioxidant/high polyphenol compound that can reduce the oligomer formation of A β 42. In the presence of equimolar cocoa extracts, dimers, pentamers, and hexamers of A β 42 were not formed while trimers and tetramers were greatly reduced. When looking at A β 40 similar decreases were seen; trimers and tetramers were completely blocked by Levado extract and reduced by natural and Dutch cocoa extracts while dimers were reduced by Levado, natural, and Dutch cocoa extracts⁸⁸. A second in-vitro study looked at supplementation of cocoa extract and its protection from A β cytotoxicity due to oxidative stress. Researchers found the toxicity was attenuated and cell viability was increased with treatment of cocoa extract⁸⁹.

Lycopene, found in tomatoes and tomato products, is a carotenoid with strong neuroprotective, antioxidant, and anti-inflammatory activity. Lycopene is also studied due to its ability to cross the blood brain barrier and to specifically act as an antioxidant in the brain. One in-vitro study pre-treated primary cultured cortical neurons with lycopene, followed by A β ₂₅₋₃₅. Although researchers utilized the shorter, less toxic form of A β , they stated the peptide utilized in their experiments is shown to "...retain the toxicity of the full length A β ..."⁹⁰. What researchers found was the pre-treatment of lycopene significantly protected against neurotoxicity by reducing apoptosis and decreasing concentrations of ROS's in a dose dependent manner⁹⁰.

4. Cholinergic Hypothesis

The cholinergic hypothesis of AD is based on ACh, the major neurotransmitter within the cholinergic system, playing an important role in memory and learning⁷. ACh synthesis occurs in the presynaptic nerve terminal and is the byproduct of the enzyme choline acetyltransferase on

Acetyl Coenzyme A (Acetyl CoA) and choline. After ACh is synthesized, it is released into the synaptic cleft where it attaches to presynaptic and postsynaptic receptors, which in turn regulates both neurotransmission and further release of ACh. At this point ACh is broken down by acetylcholinesterase (AChE) into acetate and choline which go back into circulation to produce additional ACh⁹¹. During the development of AD (as well as in the ageing process), a loss of cholinergic function in the central nervous system (CNS) occurs and is associated with a measurable decrease in the amount of ACh and an increase in total cholinesterase in the brain^{7,92}. This loss of ACh is hypothesized to contribute to cognitive decline⁷. Currently, the majority of pharmacological treatments for AD focus on AChE inhibition in order to slow down the breakdown of ACh which subsequently causes an increase in synaptic concentration of ACh as well as its neurotransmission regulatory effects. At this time, AChE inhibitors offer only modest, short-term relief during the early stages of cognitive decline⁹¹.

Butyrylcholinesterase (BuChE) is a second neurotransmitter within the cholinergic system that is important in cholinergic neurotransmission regulation as well as the development of the nervous system⁸. In 41-80% of patients with advanced AD, BuChE activity is significantly enhanced while AChE is decreased by 10-60% in the area of amyloid plaques and NFTs. Traditional treatment for AD targets AChE in order to prevent the breakdown of ACh, which delays the onset of AD but does not stop the progression of the disease⁸. Interestingly, when BuChE is inhibited, a dose-dependent increase of ACh is seen in the brain with BuChE remaining unaffected by increasing concentrations of ACh⁹¹. See Table 2 for examples of dietary components that may play a role in the cholinergic hypothesis for AD development.

5. NMDA Receptor

NMDA receptors play an important role in short and long-term memory, synaptic plasticity, and learning. When overstimulated it can produce free radicals and cause cognitive defects through neuron death^{7,93}. NMDA receptor is a glutamate receptor that can either be bound to glutamate (an excitatory neurotransmitter) or glycine (an allosteric modulator)⁹³. In normal conditions, glutamate homeostasis prevents the overaccumulation of glutamate. Additionally, NMDA receptors are highly sensitive with regulation occurring via PrP^C. Higher concentrations of PrP^C reduce the expression of NMDA receptors. During the pathogenesis of AD, increasing concentrations of A β in the brain causes overstimulation of glutamate, simultaneously A β binds to PrP^C, removing its inhibitory role on NMDA receptor causing its concentration to increase. Excitotoxicity then causes the production of ROS, leading to neuron death, cognitive dysfunction, and ultimately AD⁹⁴.

Simultaneously, excitotoxicity causes an influx of calcium through the NMDA receptor which disrupts learning and memory and causes death to the cell^{7,94}. In one study, walnuts were found to simultaneously increase NMDA receptor activity while decreasing excitotoxicity⁹⁵. Researchers believed it was the combination of polyunsaturated fatty acids, antioxidants, and polyphenols found in walnuts that provided this neuroprotective effect as seen through decreasing concentrations of lipid peroxidation⁹⁵. Similarly, another study looking at supplementation of vitamin D in rats found that rats consuming vitamin D had an increase in the expression of NMDA receptors which was positively associated with cognitive function⁹⁶.

Research into the effects of vitamin E on NMDA receptors has also been conducted. In-vitro research on mouse embryonic stem cells induced toxicity of glutamate followed by treatment with either α -tocopherol or tocotrienol rich fraction (TRF) which was composed of 25% tocopherol and 75% tocotrienol. This post-treatment of cells with vitamin E was conducted in

order to assess the neurorecovery properties of vitamin E against glutamate toxicity. Researchers found posttreatment with α -tocopherol and TRF reduced cell death in a dose-dependent manner with TRF having a greater effect than α -tocopherol alone. This increase in cell viability occurred due to α -tocopherol and TRF acting as antioxidants and reducing levels of ROS⁸².

6. Altered Calcium Homeostasis

Research into mitochondrial health has indicated that as we age the function of the mitochondria declines. This is important because the mitochondria are not only the site where bodies produce the majority of ATP for energy, but they also assist in maintaining calcium homeostasis⁷. Research has shown a decrease in mitochondrial function in AD patients within brain, fibroblasts, and blood cells^{97,98}. Mitochondria dysfunction begins with a reduction in enzymatic activity within the mitochondria. This leads to defects in the electron transport chain, altered calcium homeostasis, and eventually AD due to increasing the likelihood of A β production and deposition⁷.

Effect of nutraceuticals on mitochondria

The composition of lipids in the mitochondrial membrane changes with age. One study suggests that as people grow older, the percentage of phospholipids containing DHA in the mitochondrial membrane increases⁹⁹. The ability of mitochondrial membranes to change lipid composition as a result of a change in diet has been demonstrated in 8-month-old zebrafish, whose mitochondrial membranes contained a higher percentage of DHA after a diet high in DHA¹⁰⁰. The same effect was found in eicosapentaenoic acid (EPA), another omega-3 fatty acid¹⁰¹; although additional research suggests that while DHA and EPA exhibit many similar biological effects, research has indicated that EPA, but not DHA, improved protein quality in mitochondria and mitigated loss of mitochondrial function in aged mice¹⁰². One human study

showed a substantial reduction in the risk of all-cause dementia for individuals who were in the highest quartile of plasma DHA levels¹⁰³.

Resveratrol (as an antioxidant) has been found to pick up electrons that have been leaked from the respiratory chain, increase the formation of antioxidant species, and participate in mitochondrial energy biogenesis¹⁰⁴. One study showed resveratrol increased cell survival by mitigating the levels of ROS in the mitochondria, although the same study suggested that resveratrol increases the total amount of ROS in the cell⁸³. As stated previously, resveratrol activates SIRT1, which in addition to its anti-amyloid properties, regulates mitochondria function and energy metabolism¹⁰⁵. Several polyphenols, including resveratrol, were found to affect mitochondrial biogenesis by upregulating the promoter of mitochondrial transcription factor A (Tfam)¹⁰⁶. Other studies, however, suggest resveratrol actually induces apoptosis by upregulating the release of cytochrome c from the mitochondria, and increasing the expression of proapoptotic proteins while downregulating antiapoptotic proteins¹⁰⁷.

Like resveratrol, curcumin is an antioxidant that has demonstrated neuroprotective effects by mitigating oxidative stress caused by mitochondrial dysfunction¹⁰⁸. In the kidneys of diabetic mice, curcumin also protects mitochondria from the effects of hyperglycemia by modifying oxygen consumption rate, nitric oxide synthesis, and the levels of thiobarbituric acid-reactive substances (TBARS)¹⁰⁹. A hybrid compound of curcumin and melatonin has been found to upregulate the expression of complexes I, II, and IV of the electron transport chain in mitochondria in the brain tissue of APP/PS1 mice¹¹⁰. Experiments with cancer cells in-vivo and adipocytes in-vitro have suggested that curcumin, as well as several derivatives, including bisdemethoxycurcumin (BDMC), can induce apoptosis by inducing the release of cytochrome c

from the mitochondria^{111,112}. In contrast, a study using diabetic rat testicular cells has suggested that curcumin protects against mitochondria-dependent apoptosis¹¹³.

In an in-vitro study, researchers indicated that vitamin D downregulates respiratory chain transcription in these cells and upregulates biosynthetic pathways instead, thus increasing cell growth and proliferation¹¹⁴. A similar study indicated vitamin D acts as a gatekeeper for the mitochondrial respiratory chain by suppressing the transcription of cytochrome c oxidase subunits II and IV. This downregulates the Krebs cycle and directs the cell toward biosynthetic pathways¹¹⁵. Interestingly, vitamin D receptors can be transferred from the nucleus to the mitochondria which would help to increase the biosynthetic pathways¹¹⁶.

One in-vivo study on lycopene injected rats with A β 42 and observed how treatment with lycopene at doses of 1, 2, and 4 mg/kg orally impacted their mitochondrial activity. What researchers found was a significant increase in mitochondrial complex enzyme (I, II, and IV) in both the cerebral cortex and hippocampus along with a significant restoration of mitochondrial redox activity. Additionally, lycopene treated rats performed better than control in a Morris water maze test¹¹⁷.

A high-resolution respirometry system revealed A β and tau may work synergistically to reduce the oxidative phosphorylation capacity of mitochondria through chronic oxidative stress¹¹⁸. It has also been suggested that A β derived from the endoplasmic reticulum (ER), Golgi apparatus, or mitochondria-associated ER membranes (MAM) accumulates in the mitochondria, which disrupts Ca²⁺ homeostasis and increases the production of free radicals¹¹⁹. The above listed research into the effect of nutraceuticals on apoptosis has been conducted in murine muscle cells, breast and gastric cancer cells, human adipocytes, diabetic rats with testicular abnormalities, and human proliferating keratinocytes^{106,107,111-115}. The variety of cell types

used can possibly explain some of the opposing effects seen in resveratrol and curcumin (Figure 3).

7. Impaired Glucose Metabolism

A more recent hypothesis on the development of AD is it is caused by impaired glucose metabolism in the brain. Individuals diagnosed with type 2 diabetes in their mid-life as opposed to later in life are 1.5 times more likely to develop AD. Brain glucose hypometabolism can be detected through tomography imaging and is proposed as a possible tool for early diagnosis of AD. This link between glucose hypometabolism and AD development focuses on diets that are high in carbohydrates (with an emphasis on fructose and fructose-containing carbohydrates), inhibiting the liver from creating lipoproteins. This decrease in lipoprotein formation starve neurons of these nutrients causing the cascade effect of neurodegeneration¹⁰. One study showed a negative correlation between glycemic load dietary pattern and overall cognition and performance on various neuropsychometric tests¹²⁰.

In one in-vitro study, cultured rat hippocampal cells were exposed to A β 42, causing a reduction in the number of cells and neurite length. For cells simultaneously exposed to β -hydroxybutyrate (a ketone body) they doubled the number of surviving cells and increased neurite overgrowth¹²¹. In two in-vivo studies, a ketogenic diet was found to reduce the overall volume of formed A β with one showing decreased concentrations of NFTs and improved cognitive function^{122,123}. In one human study, 15 participants maintained a ketogenic diet with medium chain triglyceride (MCT) oil supplementation. In participants who maintained ketosis, a significant improvement in the AD Assessment Scale cognitive subscale score was observed. After participants returned to their previous diet their cognitive functions returned to baseline¹²⁴.

One case study placed the participant on a ketogenic diet along with high intensity interval training (HIIT) until ketosis was reached. After sustained ketosis their Hemoglobin A1C was within normal limits and an improvement in spatial awareness and self-efficacy was evident each week¹²⁵. A second case study had a patient consume a ketogenic and calorie restricted diet in addition to HIIT exercises. This patient entered ketosis within three weeks and saw a 26% increase in memory function score from baseline¹²⁶.

8. Pathogenic Viral

The pathogenic viral hypothesis on AD progression is fairly new, with research conducted in 2018 suggesting certain viruses, like herpes simplex virus, may be responsible for the long and slow progression of AD¹². Research had previously indicated that microbes are able to stimulate the formation of A β as a defense mechanism to stop the infectious process¹²⁷. In genetic analysis, researchers found differential gene expression associated with various viruses like Epstein-Barr virus (EBV) and human herpesvirus 6A (HHV-6A) and sought to determine if patients diagnosed with AD showed genetic changes caused by viruses. What researchers found was an increased quantity of HHV-6A and human herpesvirus 7 (HHV-7) in the brains of patients who had passed away from AD¹². Conducting a quick PubMed review of herpes simplex virus & diet brings up 58 articles but research into the way diet can reduce the impact of herpes simplex virus is lacking.

9. Prion Disease

In the prion disease hypothesis, A β oligomers bind to PrP^c receptors on neurons and initiate signaling transduction pathways that ultimately lead to neuronal death¹²⁸⁻¹³¹. In-vitro analysis has indicated PrP^c is capable of mediating the toxic effects of A β due to A β ₄₂ having a high affinity for PrP^c¹³². Subsequent in-vivo analysis determined PrP^c was essential for the

toxicity caused by A β and mice lacking PrP^c who had amyloid plaques showed no spatial learning or memory impairment¹³³. When conducting a PubMed review of PrP^c associated with AD and diet only three articles came back¹³⁴⁻¹³⁶. None of these articles discussed the impact diet has on the development of AD via prion disease.

Summary

In 1906, Dr. Alois Alzheimer first described amyloid plaques and NFTs¹³⁷. What has become clear since that time is AD is more confusing than researchers initially imagined. In this paper, a discussion was had on some of the more popular hypotheses surrounding AD development, many of which are hard to distinguish from each other due to their similarities. Between the amyloid, tau, oxidative stress, cholinergic, NMDA, altered calcium homeostasis, impaired glucose metabolism in the brain, pathogenic virus, and prion disease hypotheses it becomes apparent how interconnected many of them are. For instance, does the generation of amyloid plaques cause ROS to form or does oxidative stress form ROS leading to the development of amyloid plaques? With all of the compelling research on the nine potential pathways it becomes apparent that AD likely utilizes multiple pathways simultaneously, creating some type of interconnected loop.


Even more confusing than the cause of AD, is the role that diet plays on protecting humans from developing it. Human studies on diet and AD are limited and typically occur after an individual is already displaying signs of cognitive dysfunction^{35-38,48,49,103,124-126}. At that point in time, all of the research is focused on slowing the pace of cognitive decline because of AD's irreversible nature. Many of the bioactive compounds found commonly in plants, such as walnuts, berries, and dark leafy greens, can potentially modulate the formation of AD in multiple ways. Through this research we've learned the importance of antioxidants to remove ROS and

decrease amyloid load by targeting the various enzymes in the accumulation of amyloid plaques. Although the large majority of studies are looking at how diet impacts AD after it has already begun, the question remains, what is the right diet for a prolonged healthy life? While the evidence points towards the Mediterranean diet as an excellent option for long term health, does the MIND diet help slow the rate of cognitive decline once AD has started? What these diets have in common is a high consumption of antioxidant, anti-inflammatory, whole plant-based foods. Consuming these foods, like EVOO and resveratrol may help the body fight AD by decreasing the amount of ROS, keeping the mitochondria healthy, and reducing the potential build-up of amyloid plaques. One human study analyzed dietary patterns in patients over the course of 3.9 years and compared it to their degree of AD risk. What researchers found was a dietary pattern that was significantly associated with reduced risk of AD. It was also positively correlated with consumption of "...salad dressing, nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits and dark and green leafy vegetables..." and negatively correlated with a consumption of "...high-fat dairy, red meat, organ meat, and butter..."¹³⁸.

Looking forward, research needs to focus more on all of the lifestyle factors that contribute to AD. A question remains about whether individuals genetically predisposed to AD can impact its development through modifying their lifestyle. Garcia-Escudero et al and Weuve et al have written about how not only diet, but disease state, age, socioeconomic status, and educational level all impact the development of AD⁵. African Americans are 2-3 times more likely than whites to have cognitive impairment as they age¹³⁹. In fact, one study showed that stress over the course of your lifetime is associated with decreased cognition later in life with African Americans reporting higher stressful events in their lives¹⁴⁰. In addition, a quick search of K-12 nutrition education programs shows that nutrition education comes from after school


programs and the school nutrition program, who is responsible for providing meals to children. From a nutritional standpoint it is easy to emphasize consuming a diet that is high in antioxidant, anti-inflammatory, whole foods; however, before recommending this, it is important to recognize what the possible barriers are to an individual getting what they need. Knowing whether they live in a food desert, what their financial/transportation situation is, and what education they have received about eating healthy can lead the conversation. In the previous study linking dietary patterns with risk of AD, the population consuming the diet with the lowest risk of AD tended to be younger, more educated, non-current smokers¹⁴¹. Future research needs to focus on bringing nutrition education to everyone and reducing the health disparities. Through incorporating education in the classrooms from a young age, a longitudinal study could show us the impact of a low-risk AD healthy diet throughout the life instead of focusing on preventing the further development of a disease that currently has no cure.

Figure 1: Summary of hypothesis leading to the development of Alzheimer's Disease.



Aβ: beta-amyloid protein; ROS: reactive oxygen species; ETC: electron transport chain; ACh: Acetylcholine; TChE: Total Cholinesterase; CNS: Central Nervous System; NMDA: N-methyl-d-aspartate

Figure 2: Effects of diet on the amyloid hypothesis of Alzheimer's Disease development



Adapted from Rosenberg, et al¹⁸. DHA: docosahexaenoic acid; EGCG: epigallocatechin gallate; EVOO: extra virgin olive oil

Table 1: Summary of research into the impact of vitamin E isoforms on the amyloid hypothesis.

α -tocopherol	<ul style="list-style-type: none"> • Higher intake associated with reduced AD risk⁶²⁻⁶⁴ • If γ-tocopherol levels are low, higher α-tocopherol levels are associated with higher Aβ load⁶⁴ • In-vivo study showed dietary supplementation along with N-acetylcysteine and alpha-lipoic acid prevented cognitive decline¹⁴² • α-tocopherol quinone is an oxidative metabolite of α-tocopherol and has been shown to improve memory in in-vitro studies¹⁴³ • α-tocopherol + α-tocopherol quinone shown to decrease Aβ accumulation and toxicity¹⁴²
γ -tocopherol	<ul style="list-style-type: none"> • Higher plasma levels associated with lowered AD neuropathology¹⁴⁴ • One in-vitro study showed increased Aβ secretion with treatment due to increased expression of β- and γ-secretase¹⁴⁵
δ -tocopherol	<ul style="list-style-type: none"> • One in-vitro study showed increased Aβ secretion with treatment due to increased expression of β- and γ-secretase¹⁴⁵
α -tocopherol + α -, β -, γ -, δ -tocotrienol supplement	<ul style="list-style-type: none"> • In-vitro analysis indicates it disrupts formation of Aβ₄₂¹⁴⁶ • In-vivo analysis indicated an improvement in cognitive impairment and a decrease in Aβ deposition with supplementation¹⁴⁶


AD: Alzheimer's Disease; A β : beta-amyloid protein

Table 2: Summary of research into dietary nutrients impact on the cholinergic hypothesis.

Alkaloids	Largest group of metabolites with ChE inhibitory activity at lower concentrations. Examples include physostigmine which decreases AChE but not BuChE and berberine, an isoquinoline alkaloid that inhibits ChEs and β -secretase activity in rabbits, and galantamine ⁸
Brava Oil	Showed dose dependent inhibition of BuChE and AChE ¹⁴⁷
Coumarins	Display AChE inhibition with some showing good BuChE inhibition ⁸
Flavonoids	Along with isoflavones have higher AChE activity. The number of hydroxyl groups on the B ring of a flavonoid influences the potency of BuChE inhibition with an increase in the number of hydroxyl groups decreasing BuChE inhibition. Examples include Galangin, a type of flavanol had strong anti-ChE activity with the most potent activity against BuChE ⁸
Lycopene	In-vivo study showed reversal of AChE activity and improved performance on Morris water maze test ¹¹⁷
Mansa Oil	Showed dose dependent inhibition of BuChE but not AChE ¹⁴⁷
Prenyltransferase Inhibitors	Have been used to rescue synaptic and cognitive deficits caused by overactivation of farnesylated proteins. GGTIs can act directly on neuronal cells and the CNS ¹⁴⁸
Quinones	Pro-oxidants needed for mitochondria respiration. Redox reactions may occur creating semiquinones and hydroquinones which can create additional ROS. Some also work as AChEi ⁸
Spanish Sage	Inhibit AChE, is an antioxidant, anti-inflammatory, and displays estrogenic effects. Estrogenic agents are potentially protective in preventing or delaying neurodegeneration in AD ¹⁴⁹
Stilbenes	Secondary metabolites derived from phenylpropanoid pathway and includes Resveratrol. Stilbenes other than resveratrol (like Gnetol) have better AChE and BuChEi activity ⁸
Terpenic Compounds	Built up from isoprene subunits and are the most numerous and structurally diverse group of secondary metabolites produced by plants. It takes higher concentrations of terpenes to inhibit ChE. Dihydrotanshinone and cryptotanshinone have the potential to cross the BBB ⁸
Tocotrienols	Tocotrienols appear to be superior to tocopherols because of their better distribution in the fatty layers of the cell membrane. Overall reduces free radical markers decreases AChE ¹⁵⁰
Xanthones	Secondary metabolites produced by plants, fungi, and lichens. Generally weak ChE inhibitors but with a lipophilic side chain it improves ⁸
Vitamin A	In-vivo studies indicate restored AChE activity with supplementation of all-trans retinoic acid ¹⁵¹

AChE: Acetylcholinesterase; AChEi: Acetylcholinesterase inhibitor; AD: Alzheimer's Disease; BBB: Blood Brain Barrier; BuChE: Butyrylcholinesterase; BuChEi: Butyrylcholinesterase inhibitor; ChE: Cholinesterase;; GGTIs: Geranylgeranyl Transferase Inhibitor; ROS: Reactive Oxygen Species

Figure 3: Cell type dependent effect of nutraceuticals on apoptosis



Curcumin and resveratrol have shown opposing effects on mitochondria apoptosis depending on cell type. Vitamin D on the other hand has been shown to increase apoptosis.

References

1. Chen XQ, Mobley WC. Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A β and Tau Species. *Front Neurosci*. 2019;13:659:eCollection.
2. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. *Neurology*. 2013;80(19):1778-1783.
3. Ferrier PCCRAHDR. *Biochemistry*. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2008.
4. Ageing NIo. Alzheimer's Disease Fact Sheet. Published 2019. Updated May 22, 2019. Accessed June 1, 2019.
5. Garcia-Escudero PF-SDR-GV. Modulating Effect of Diet on Alzheimer's Disease. *Diseases*. 2019;26(7(1)).
6. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol*. 2006;112(4):389-404.
7. Omar SH, Scott CJ, Hamlin AS, Obied HK. The protective role of plant biophenols in mechanisms of Alzheimer's disease. *J Nutr Biochem*. 2017;47:1-20.
8. Pinho BR, Ferreres F, Valentao P, Andrade PB. Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment. *J Pharm Pharmacol*. 2013;65(12):1681-1700.
9. Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. *Biochem Pharmacol*. 2010;80(11):1613-1631.
10. Broom GM, Shaw IC, Rucklidge JJ. The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease. *Nutrition*. 2019;60:118-121.
11. Przedborski S, Vila M, Jackson-Lewis V. Neurodegeneration: what is it and where are we? *J Clin Invest*. 2003;111(1):3-10.
12. Readhead B, Haure-Mirande JV, Funk CC, et al. Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron*. 2018;99(1):64-82 e67.
13. Zhou J, Liu B. Alzheimer's disease and prion protein. *Intractable Rare Dis Res*. 2013;2(2):35-44.
14. Medicine JH. Prion Diseases. Published 2019. Accessed July 25, 2019.
15. Bhushan A, Fondell E, Ascherio A, Yuan C, Grodstein F, Willett W. Adherence to Mediterranean diet and subjective cognitive function in men. *Eur J Epidemiol*. 2018;33(2):223-234.
16. Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. *Alzheimers Dement*. 2015;11(9):1015-1022.
17. Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. *Alzheimers Dement*. 2015;11(9):1007-1014.
18. Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. Genomics of Alzheimer Disease: A Review. *JAMA Neurol*. 2016;73(7):867-874.
19. Zhang X, Li Y, Xu H, Zhang YW. The gamma-secretase complex: from structure to function. *Front Cell Neurosci*. 2014;8:427.

20. Feng X, Liang N, Zhu D, et al. Resveratrol inhibits beta-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. *PLoS One*. 2013;8(3):e59888.
21. Shimizu K, Funamoto M, Sunagawa Y, et al. Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases. *Eur Cardiol*. 2019;14(2):117-122.
22. Lee JW, Lee YK, Ban JO, et al. Green tea (-)-epigallocatechin-3-gallate inhibits β -amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF- κ B pathways in mice. *Journal of Nutrition*. 2009;139(10):1987-1993.
23. Zhao Y, Calon F, Julien C, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR γ -mediated mechanisms in Alzheimer's disease models. *PloS one*. 2011;6(1):e15816.
24. Narasingappa RB, Javagal MR, Pullabhatla S, et al. Activation of alpha-secretase by curcumin-aminoacid conjugates. *Biochem Biophys Res Commun*. 2012;424(4):691-696.
25. Park SY, Kim HS, Cho EK, et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. *Food Chem Toxicol*. 2008;46(8):2881-2887.
26. Okello EJ, Savelev SU, Perry EK. In vitro anti-beta-secretase and dual anti-cholinesterase activities of *Camellia sinensis* L. (tea) relevant to treatment of dementia. *Phytother Res*. 2004;18(8):624-627.
27. Goncalves MB, Clarke E, Hobbs C, et al. Amyloid beta inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor alpha agonist. *Eur J Neurosci*. 2013;37(7):1182-1192.
28. Koryakina A, Aeberhard J, Kiefer S, Hamburger M, Kuenzi P. Regulation of secretases by all-trans-retinoic acid. *FEBS J*. 2009;276(9):2645-2655.
29. Briones TL, Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. *J Neuroinflammation*. 2012;9:244.
30. Durk MR, Han K, Chow EC, et al. 1 α ,25-Dihydroxyvitamin D₃ reduces cerebral amyloid-beta accumulation and improves cognition in mouse models of Alzheimer's disease. *J Neurosci*. 2014;34(21):7091-7101.
31. Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D₃-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP transgenic mice. *J Alzheimers Dis*. 2011;25(2):295-307.
32. Taghizadeh M, Djazayeri A, Salami M, Eshraghian MR, Zavareh SA. Vitamin-D-free regimen intensifies the spatial learning deficit in Alzheimer's disease. *Int J Neurosci*. 2011;121(1):16-24.
33. Grimm MO, Zimmer VC, Lehmann J, Grimm HS, Hartmann T. The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. *Biomed Res Int*. 2013;2013:814390.
34. Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. *J Biol Chem*. 2008;283(17):11302-11311.
35. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *N Engl J Med*. 1997;336(17):1216-1222.

36. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. *JAMA*. 2014;311(1):33-44.
37. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005;352(23):2379-2388.
38. Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch Neurol*. 2012;69(7):836-841.
39. Ladiwala AR, Lin JC, Bale SS, et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. *J Biol Chem*. 2010;285(31):24228-24237.
40. Fu Z, Aucoin D, Ahmed M, Ziliox M, Van Nostrand WE, Smith SO. Capping of abeta42 oligomers by small molecule inhibitors. *Biochemistry*. 2014;53(50):7893-7903.
41. Huy PD, Yu YC, Ngo ST, et al. In silico and in vitro characterization of anti-amyloidogenic activity of vitamin K3 analogues for Alzheimer's disease. *Biochim Biophys Acta*. 2013;1830(4):2960-2969.
42. Hossain S, Hashimoto M, Katakura M, Miwa K, Shimada T, Shido O. Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-S5Y5 cells. *J Neurochem*. 2009;111(2):568-579.
43. Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. *J Neurosci*. 2005;25(38):8807-8814.
44. Choi YT, Jung CH, Lee SR, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. *Life Sci*. 2001;70(5):603-614.
45. Zhao LN, Chiu SW, Benoit J, Chew LY, Mu Y. The effect of curcumin on the stability of Abeta dimers. *J Phys Chem B*. 2012;116(25):7428-7435.
46. Rezai-Zadeh K, Arendash GW, Hou H, et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. *Brain Res*. 2008;1214:177-187.
47. Wang C, Zhang X, Teng Z, Zhang T, Li Y. Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice. *Eur J Pharmacol*. 2014;740:312-320.
48. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. *J Clin Psychopharmacol*. 2008;28(1):110-113.
49. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. *Neurology*. 2008;71(2):85-92.
50. Masoumi A, Goldenson B, Ghirmai S, et al. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. *J Alzheimers Dis*. 2009;17(3):703-717.
51. Qosa H, Mohamed LA, Batarseh YS, et al. Extra-virgin olive oil attenuates amyloid- β and tau pathologies in the brains of TgSwDI mice. *The Journal of Nutritional Biochemistry*. 2015;26(12):1479-1490.
52. Supplements NIOHOoD. Omega-3 Fatty Acids. Published 2019. Accessed July 24, 2019.

53. Aparicio-Soto M, Sanchez-Hidalgo M, Rosillo MA, Castejon ML, Alarcon-de-la-Lastra C. Extra virgin olive oil: a key functional food for prevention of immune-inflammatory diseases. *Food Funct.* 2016;7(11):4492-4505.
54. Durairajan SS, Yuan Q, Xie L, et al. Salvianolic acid B inhibits A β fibril formation and disaggregates preformed fibrils and protects against A β -induced cytotoxicity. *Neurochemistry International.* 2008;52(4-5):741-750.
55. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. *Prog Neurobiol.* 2005;75(4):275-293.
56. Sodhi RK, Singh N. Retinoids as potential targets for Alzheimer's disease. *Pharmacol Biochem Behav.* 2014;120:117-123.
57. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, et al. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. *Age Ageing.* 2001;30(3):235-241.
58. Kipen E, Helme RD, Wark JD, Flicker L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. *J Am Geriatr Soc.* 1995;43(10):1088-1091.
59. Rinaldi P, Polidori MC, Metastasio A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. *Neurobiol Aging.* 2003;24(7):915-919.
60. Mangialasche F, Xu W, Kivipelto M, et al. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. *Neurobiology of Aging.* 2012;33(10):2282-2290.
61. Lopes da Silva S, Vellas B, Elemans S, et al. Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis. *Alzheimers Dement.* 2014;10(4):485-502.
62. Mangialasche F, Kivipelto M, Mecocci P, et al. High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. *J Alzheimers Dis.* 2010;20(4):1029-1037.
63. Li FJ, Shen L, Ji HF. Dietary intakes of vitamin E, vitamin C, and beta-carotene and risk of Alzheimer's disease: a meta-analysis. *J Alzheimers Dis.* 2012;31(2):253-258.
64. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. *Am J Clin Nutr.* 2005;81(2):508-514.
65. Presse N, Shatenstein B, Kergoat MJ, Ferland G. Low vitamin K intakes in community-dwelling elders at an early stage of Alzheimer's disease. *J Am Diet Assoc.* 2008;108(12):2095-2099.
66. Shatenstein B, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. *J Am Diet Assoc.* 2007;107(12):2091-2099.
67. Sato Y, Honda Y, Hayashida N, Iwamoto J, Kanoko T, Satoh K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. *Arch Phys Med Rehabil.* 2005;86(3):576-581.
68. Saupe J, Shearer MJ, Kohlmeier M. Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. *Am J Clin Nutr.* 1993;58(2):204-208.

69. Carrie I, Belanger E, Portoukalian J, Rochford J, Ferland G. Lifelong low-phyloquinone intake is associated with cognitive impairments in old rats. *J Nutr.* 2011;141(8):1495-1501.
70. Liu M, Chen F, Sha L, et al. (-)-Epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1 transgenic mice. *Mol Neurobiol.* 2014;49(3):1350-1363.
71. Yu CC, Jiang T, Yang AF, Du YJ, Wu M, Kong LH. Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease. *Neural Plast.* 2019;2019:6856327.
72. Ho L, Yemul S, Wang J, Pasinetti GM. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. *J Alzheimers Dis.* 2009;16(2):433-439.
73. Taniguchi S, Suzuki N, Masuda M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. *J Biol Chem.* 2005;280(9):7614-7623.
74. Daccache A, Lion C, Sibille N, et al. Oleuropein and derivatives from olives as Tau aggregation inhibitors. *Neurochem Int.* 2011;58(6):700-707.
75. Wang J, Santa-Maria I, Ho L, et al. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. *J Alzheimers Dis.* 2010;22(2):653-661.
76. Wang YJ, Thomas P, Zhong JH, et al. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. *Neurotox Res.* 2009;15(1):3-14.
77. Watamura N, Toba J, Yoshii A, Nikkuni M, Ohshima T. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer's disease model mice: Involvement of Cdk5 phosphorylation and the effect of ATRA treatment. *J Neurosci Res.* 2016;94(1):15-26.
78. Ding Y, Qiao A, Wang Z, et al. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. *J Neurosci.* 2008;28(45):11622-11634.
79. Giraldo E, Lloret A, Fuchsberger T, Vina J. Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E. *Redox Biol.* 2014;2:873-877.
80. Nakashima H, Ishihara T, Yokota O, et al. Effects of alpha-tocopherol on an animal model of tauopathies. *Free Radic Biol Med.* 2004;37(2):176-186.
81. Carlsen MH, Halvorsen BL, Holte K, et al. The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. *Nutr J.* 2010;9:3.
82. Abd Jalil A, Khaza'ai H, Nordin N, Mansor N, Zaulkffali AS. Vitamin E-Mediated Modulation of Glutamate Receptor Expression in an Oxidative Stress Model of Neural Cells Derived from Embryonic Stem Cell Cultures. *Evid Based Complement Alternat Med.* 2017;2017:6048936.
83. Babu D, Leclercq G, Goossens V, et al. Antioxidant potential of CORM-A1 and resveratrol during TNF-alpha/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial MODE-K cells. *Toxicol Appl Pharmacol.* 2015.
84. Parthasarathy L, Khadilkar V, Chiplonkar S, Khadilkar A. Effect of Antioxidant Supplementation on Total Antioxidant Status in Indian Children with Type 1 Diabetes. *J Diet Suppl.* 2019;16(4):390-400.

85. Smith SSGJL. *Advanced Nutrition and Human Metabolism*. sixth ed. Belmont, CA: Wadsworth; 2013.
86. Kwon KJ, Kim HJ, Shin CY, Han SH. Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways. *J Clin Neurol*. 2010;6(3):127-137.
87. Wen H, Fu Z, Wei Y, et al. Antioxidant Activity and Neuroprotective Activity of Stilbenoids in Rat Primary Cortex Neurons via the PI3K/Akt Signalling Pathway. *Molecules*. 2018;23(9).
88. Wang J, Varghese M, Ono K, et al. Cocoa extracts reduce oligomerization of amyloid-beta: implications for cognitive improvement in Alzheimer's disease. *J Alzheimers Dis*. 2014;41(2):643-650.
89. Heo HJ, Lee CY. Epicatechin and catechin in cocoa inhibit amyloid β protein induced apoptosis. *J Agric Food Chem*. 2005;53(5):1445-1448.
90. Qu M, Li L, Chen C, et al. Protective effects of lycopene against amyloid beta-induced neurotoxicity in cultured rat cortical neurons. *Neurosci Lett*. 2011;505(3):286-290.
91. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. *Annu Rev Med*. 2006;57:513-533.
92. Wang S, Cui Y, Wang C, et al. Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. *PLoS One*. 2015.
93. Zhang P, Xu S, Zhu Z, Xu J. Multi-target design strategies for the improved treatment of Alzheimer's disease. *Eur J Med Chem*. 2019;176:228-247.
94. Black SA, Stys PK, Zamponi GW, Tsutsui S. Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. *Front Cell Dev Biol*. 2014;2:45.
95. Hicyilmaz H, Vural H, Delibas N, Sutcu R, Gultekin F, Yilmaz N. The effects of walnut supplementation on hippocampal NMDA receptor subunits NR2A and NR2B of rats. *Nutr Neurosci*. 2017;20(3):203-208.
96. Zong L, Chu P, Huang P, Guo Y, Lv Y. Effect of vitamin D on the learning and memory ability of FGR rat and NMDA receptor expression in hippocampus. *Exp Ther Med*. 2017;14(1):581-586.
97. Parker WD, Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology*. 1990;40(8):1302-1303.
98. Valla J, Schneider L, Niedzielko T, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. *Mitochondrion*. 2006;6(6):323-330.
99. Norris SE, Friedrich MG, Mitchell TW, Truscott RJ, Else PL. Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. *Neurobiology of aging*. 2015;36(4):1659-1669.
100. Betancor MB, Almada-Pagan PF, Hernandez A, Tocher DR. Effects of dietary fatty acids on mitochondrial phospholipid compositions, oxidative status and mitochondrial gene expression of zebrafish at different ages. *Fish physiology and biochemistry*. 2015.
101. Yeh A, Kruse SE, Marcinek DJ, Gallagher EP. Effect of omega-3 fatty acid oxidation products on the cellular and mitochondrial toxicity of BDE 47. *Toxicology in vitro : an international journal published in association with BIBRA*. 2015;29(4):672-680.

102. Johnson ML, Lalia AZ, Dasari S, et al. Eicosapentaenoic acid but not docosahexaenoic acid restores skeletal muscle mitochondrial oxidative capacity in old mice. *Aging cell*. 2015.
103. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. *Arch Neurol*. 2006;63(11):1545-1550.
104. Pshenichnyuk SA, Komolov AS. Dissociative Electron Attachment to Resveratrol as a Likely Pathway for Generation of the H₂ Antioxidant Species Inside Mitochondria. *The journal of physical chemistry letters*. 2015;6(7):1104-1110.
105. Wakino S, Hasegawa K, Itoh H. Sirtuin and metabolic kidney disease. *Kidney international*. 2015.
106. Yoshino M, Naka A, Sakamoto Y, et al. Dietary isoflavone daidzein promotes Tfam expression that increases mitochondrial biogenesis in C2C12 muscle cells. *J Nutr Biochem*. 2015.
107. Gibellini L, Bianchini E, De Biasi S, Nasi M, Cossarizza A, Pinti M. Natural Compounds Modulating Mitochondrial Functions. *Evid Based Complement Alternat Med*. 2015;2015:527209.
108. Waseem M, Parvez S. Neuroprotective activities of curcumin and quercetin with potential relevance to mitochondrial dysfunction induced by oxaliplatin. *Protoplasma*. 2015.
109. Soto-Urquieta MG, Lopez-Briones S, Perez-Vazquez V, Saavedra-Molina A, Gonzalez-Hernandez GA, Ramirez-Emiliano J. Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice. *Biological research*. 2014;47(1):74.
110. Gerenu G, Liu K, Chojnacki JE, et al. Curcumin/Melatonin Hybrid 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 Mouse Model. *ACS chemical neuroscience*. 2015;6(8):1393-1399.
111. Luo C, Du Z, Wei X, Chen G, Fu Z. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. *Oncol Lett*. 2015;9(1):270-274.
112. Zhu L, Han MB, Gao Y, et al. Curcumin triggers apoptosis via upregulation of Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes. *Mol Med Rep*. 2015;12(1):1151-1156.
113. Rashid K, Sil PC. Curcumin ameliorates testicular damage in diabetic rats by suppressing cellular stress-mediated mitochondria and endoplasmic reticulum-dependent apoptotic death. *Biochim Biophys Acta*. 2015;1852(1):70-82.
114. Consiglio M, Viano M, Casarin S, Castagnoli C, Pescarmona G, Silvagno F. Mitochondrial and lipogenic effects of vitamin D on differentiating and proliferating human keratinocytes. *Exp Dermatol*. 2015.
115. Consiglio M, Destefanis M, Morena D, et al. The vitamin D receptor inhibits the respiratory chain, contributing to the metabolic switch that is essential for cancer cell proliferation. *PloS one*. 2014;9(12):e115816.
116. Calton EK, Keane KN, Soares MJ. The potential regulatory role of vitamin D in the bioenergetics of inflammation. *Current opinion in clinical nutrition and metabolic care*. 2015;18(4):367-373.

117. Sachdeva AK, Chopra K. Lycopene abrogates A β (1-42)-mediated neuroinflammatory cascade in an experimental model of Alzheimer's disease. *J Nutr Biochem*. 2015;26(7):736-744.
118. Grimm A, Schmitt K, Eckert A. Advanced Mitochondrial Respiration Assay for Evaluation of Mitochondrial Dysfunction in Alzheimer's Disease. *Methods Mol Biol*. 2016;1303:171-183.
119. Volgyi K, Juhasz G, Kovacs Z, Penke B. Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk. *Current Alzheimer research*. 2015;12(7):655-672.
120. Taylor MK, Sullivan DK, Swerdlow RH, et al. A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults. *Am J Clin Nutr*. 2017;106(6):1463-1470.
121. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. *Proc Natl Acad Sci U S A*. 2000;97(10):5440-5444.
122. Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid β 40 and 42 in a mouse model of Alzheimer's disease. *Nutr Metab (Lond)*. 2005;2:28.
123. Kashiwaya Y, Bergman C, Lee JH, et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. *Neurobiol Aging*. 2013;34(6):1530-1539.
124. Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease. *Alzheimers Dement (N Y)*. 2018;4:28-36.
125. Halikas A, Gibas KJ. AMPK induced memory improvements in the diabetic population: A case study. *Diabetes Metab Syndr*. 2018;12(6):1141-1146.
126. Dahlgren K, Gibas KJ. Ketogenic diet, high intensity interval training (HIIT) and memory training in the treatment of mild cognitive impairment: A case study. *Diabetes Metab Syndr*. 2018;12(5):819-822.
127. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid β -protein is an antimicrobial peptide. *PLoS One*. 2010;5(3):e9505.
128. Um JW, Strittmatter SM. Amyloid- β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. *Prion*. 2013;7(1):37-41.
129. Verdier Y, Zarandi M, Penke B. Amyloid β -peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. *J Pept Sci*. 2004;10(5):229-248.
130. Origlia N, Capsoni S, Cattaneo A, et al. A β -dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. *J Alzheimers Dis*. 2009;17(1):59-68.
131. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating β -amyloid from α 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes α 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. *J Neurosci*. 2009;29(35):10961-10973.
132. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid- β oligomers. *Nature*. 2009;457(7233):1128-1132.

133. Gimbel DA, Nygaard HB, Coffey EE, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. *J Neurosci.* 2010;30(18):6367-6374.
134. Toni M, Massimino ML, De Mario A, Angiulli E, Spisni E. Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. *Front Neurosci.* 2017;11:3.
135. Vintem AP, Henriques AG, da Cruz ESOA, da Cruz ESEF. PP1 inhibition by Abeta peptide as a potential pathological mechanism in Alzheimer's disease. *Neurotoxicol Teratol.* 2009;31(2):85-88.
136. Mattson MP, Sherman M. Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation. *Neuromolecular Med.* 2003;4(1-2):109-132.
137. Hippus H, Neundorfer G. The discovery of Alzheimer's disease. *Dialogues Clin Neurosci.* 2003;5(1):101-108.
138. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food Combination and Alzheimer Disease Risk: A Protective Diet. *Archives of Neurology.* 2010.
139. Weuve J, Barnes LL, Mendes de Leon CF, et al. Cognitive Aging in Black and White Americans: Cognition, Cognitive Decline, and Incidence of Alzheimer Disease Dementia. *Epidemiology.* 2018;29(1):151-159.
140. M Z, CE G, AJ K, RL K, SC J, OC O. Lifetime Stressful Experiences, racial disparities, and cognitive performance: findings from the wisconsin registry for Alzheimer's prevention (wrap) study. *Alzheimer's Dement.* 2017;13(7):P212.
141. Gu Y, Scarmeas N. Dietary Patterns in Alzheimer's Disease and Cognitive Aging. *Curr Alzheimer Res.* 2011;8:510-519.
142. Grimm MO, Mett J, Hartmann T. The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer's Disease. *Int J Mol Sci.* 2016;17(11).
143. Wang SW, Yang SG, Liu W, et al. Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease. *Behav Brain Res.* 2016;296:109-117.
144. Morris MC, Schneider JA, Li H, et al. Brain tocopherols related to Alzheimer's disease neuropathology in humans. *Alzheimers Dement.* 2015;11(1):32-39.
145. Grimm MO, Stahlmann CP, Mett J, et al. Vitamin E: Curse or Benefit in Alzheimer's Disease? A Systematic Investigation of the Impact of alpha-, gamma- and delta-Tocopherol on Ass Generation and Degradation in Neuroblastoma Cells. *J Nutr Health Aging.* 2015;19(6):646-656.
146. Ibrahim NF, Yanagisawa D, Durani LW, et al. Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AbetaPP/PS1 Mice. *J Alzheimers Dis.* 2017;55(2):597-612.
147. Figueiredo-Gonzalez M, Reboredo-Rodriguez P, Gonzalez-Barreiro C, Carrasco-Pancorbo A, Simal-Gandara J, Cancho-Grande B. Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'. *Molecules.* 2018;23(4).
148. Li L, Zhang W, Cheng S, Cao D, Parent M. Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. *Molecular Neurobiology.* 2012;46(1):64-77.

149. Perry NS, Houghton PJ, Sampson J, et al. In-vitro activity of *S. lavandulaefolia* (Spanish sage) relevant to treatment of Alzheimer's disease. *J Pharm Pharmacol*. 2001;53(10):1347-1356.
150. Tiwari V, Kuhad A, Bishnoi M, Chopra K. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. *Pharmacology, Biochemistry and Behavior*. 2009;93(2):183-189.
151. Sodhi RK, Singh N. All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer's type. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;40:38-46.